Where I see patients (2)
My reviews
Selected research
-
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
Endocrine-related cancer
-
Correction: Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report.
Cardio-oncology (London, England)
Clinical trials
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronc...
Will be compared between patients with a bronchial neuroendocrine tumor (NET) receiving lutetium Lu 177 dotatate to those receiving everolimus. The distribution of PFS will be estimated using the Kaplan Meier method. Will be teste...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 885-3882
4.9